Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.

Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 01; 17(21):6858-66.

View in: PubMed

subject areas

3-Iodobenzylguanidine
Administration, Oral
Adolescent
Antineoplastic Agents
Capsules
Child
Child, Preschool
Disease-Free Survival
Female
Fenretinide
Humans
Infant
Iodine Radioisotopes
Magnetic Resonance Imaging
Male
Neoplasm Recurrence, Local
Neuroblastoma
Radiopharmaceuticals
Survival Rate
Tomography, X-Ray Computed
Young Adult

authors with profiles

Susan L. Cohn